TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioVersys AG ( (CH:BIOV) ) has shared an update.
BioVersys AG announced the partial exercise of an over-allotment option following its successful IPO on the SIX Swiss Exchange, resulting in the issuance of an additional 47,862 new shares. This move raised the total gross proceeds to CHF76.7 million, increasing the total number of shares issued to 2,131,195. The IPO is expected to bolster BioVersys’s financial position, allowing it to further its research and development efforts in combating multidrug-resistant bacterial infections, thereby strengthening its industry positioning and offering potential benefits to stakeholders.
More about BioVersys AG
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company based in Basel, Switzerland. It focuses on the research and development of novel antibacterial products targeting serious life-threatening infections caused by multidrug-resistant bacteria. Utilizing its internal technology platforms, BioVersys aims to overcome bacterial resistance mechanisms and address high unmet medical needs in the antimicrobial and microbiome fields. Its advanced programs include treatments for nosocomial infections and tuberculosis, with collaborations involving GlaxoSmithKline and the University of Lille.
YTD Price Performance: 1.01%
Average Trading Volume: 11,705
For a thorough assessment of BIOV stock, go to TipRanks’ Stock Analysis page.